Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1960 1
1962 1
1963 1
1964 3
1965 1
1973 1
1974 1
1975 2
1976 3
1977 4
1978 1
1980 10
1981 4
1982 2
1983 3
1984 6
1985 6
1986 14
1987 9
1988 14
1989 11
1990 20
1991 17
1992 22
1993 22
1994 37
1995 36
1996 35
1997 41
1998 47
1999 48
2000 73
2001 99
2002 80
2003 121
2004 116
2005 184
2006 223
2007 262
2008 370
2009 388
2010 468
2011 593
2012 664
2013 800
2014 959
2015 1058
2016 1100
2017 1317
2018 1601
2019 1763
2020 2141
2021 2551
2022 3008
2023 2887
2024 3234
2025 3104
2026 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26,557 results

Results by year

Filters applied: . Clear all
Page 1
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: yang f. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial.
Yue D, Wang W, Liu H, Chen Q, Chen C, Liu L, Zhang P, Zhao G, Yang F, Han G, Cheng Y, Yu B, Yang Y, Chen H, Jiang J, Tan L, Xu S, Mao N, Hu J, Zhang L, Yao B, Wang S, Wang RH, Zheng W, Wang C; RATIONALE-315 investigators. Yue D, et al. Among authors: yang f. Lancet Respir Med. 2025 Feb;13(2):119-129. doi: 10.1016/S2213-2600(24)00269-8. Epub 2024 Nov 21. Lancet Respir Med. 2025. PMID: 39581197 Clinical Trial.
Host FSTL1 defines the impact of stem cell therapy on liver fibrosis by potentiating the early recruitment of inflammatory macrophages.
Zheng X, Tian S, Li T, Zhang S, Zhou X, Liu Y, Su R, Zhang M, Li B, Qi C, Guo G, Ma S, Sun K, Yang F, Hu Y, Yang C, Cui L, Shang Y, Guo C, Jin B, Guan L, Wang J, Ning W, Han Y. Zheng X, et al. Among authors: yang f. Signal Transduct Target Ther. 2025 Mar 7;10(1):81. doi: 10.1038/s41392-025-02162-6. Signal Transduct Target Ther. 2025. PMID: 40050288 Free PMC article.
PSPC1 exerts an oncogenic role in AML by regulating a leukemic transcription program in cooperation with PU.1.
Hong J, Sui P, Li Y, Xu KY, Lee JH, Wang J, Chen S, Zhang P, Wingate N, Noor A, Yuan Y, Hromas R, Zhou H, Hamamoto K, Su R, Yin CC, Ye F, Quesada AE, Chen J, Huang S, Zhou D, You MJ, Yang FC, Wang J, Xu M. Hong J, et al. Among authors: yang fc. Cell Stem Cell. 2025 Mar 6;32(3):463-478.e6. doi: 10.1016/j.stem.2025.01.010. Epub 2025 Feb 14. Cell Stem Cell. 2025. PMID: 39954676 Free article.
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, Shrimanker R, Cox C, Brightling CE, Chaudhuri R, Pavord ID, Heaney LG; Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium). McDowell PJ, et al. Among authors: yang f. Lancet Respir Med. 2021 Oct;9(10):1174-1184. doi: 10.1016/S2213-2600(21)00004-7. Epub 2021 May 7. Lancet Respir Med. 2021. PMID: 33971168
CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models.
Bao Y, Chang Y, Tien JC, Cruz G, Yang F, Mannan R, Mahapatra S, Paturu R, Cao X, Su F, Wang R, Zhang Y, Gondal M, Choi JE, Gurkan JK, Miner SJ, Robinson DR, Wu YM, Zhou L, Wang Z, Kryczek I, Wang X, Cieslik M, Qiao Y, Tsodikov A, Zou W, Ding K, Chinnaiyan AM. Bao Y, et al. Among authors: yang f. J Clin Invest. 2025 Jul 22;135(18):e193745. doi: 10.1172/JCI193745. eCollection 2025 Sep 16. J Clin Invest. 2025. PMID: 40955658 Free PMC article.
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages.
Yang DL, Ye L, Zeng FJ, Liu J, Yao HB, Nong JL, Liu SP, Peng N, Li WF, Wu PS, Qin C, Su Z, Ou JJ, Dong XF, Yan YH, Zhong TM, Mao XS, Wu MS, Chen YZ, Wang GD, Li MJ, Wang XY, Yang FQ, Liang YR, Chen SC, Yang YY, Chen K, Li FX, Lai YC, Pang QQ, Liang XM, You XM, Xiang BD, Yu YQ, Ma L, Zhong JH; GUIDANCE investigators. Yang DL, et al. Among authors: yang fq. Hepatology. 2025 Aug 1;82(2):357-369. doi: 10.1097/HEP.0000000000001229. Epub 2025 Jan 15. Hepatology. 2025. PMID: 39908184
26,557 results
You have reached the last available page of results. Please see the User Guide for more information.